Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

CompletedOBSERVATIONAL

Enrollment

1,995

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL

Peginterferon alfa-2b (SCH 54031)

Peginterferon alfa-2b will be administered according to the products' labeling.

DRUG

Ribavirin (SCH 18908)

Ribavirin will be administered according to the products' labeling.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00727259 - Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) | Biotech Hunter | Biotech Hunter